Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paricalcitol plus gemcitabine/nab-paclitaxel in advanced pancreatic cancer
2020-000073-24Phase 2Completed
- Sponsor
- Cancer Trials Ireland
- Start
- Jan 2020
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of paricalcitol in pancreatic cancer (PC), sponsored by Cancer Trials Ireland. Primary endpoint: Anti-tumour efficacy of paricalcitol in combination with gemcitabine and nab-paclitaxel. Started Jan 2020; status: completed.
02
Drugs
paricalcitol
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on 2020-000073-24.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-000073-24.